Antibacterial nanoparticles based on berberine derivatives and rhamnolipids

A technology of rhamnolipid and berberine, which can be applied in the direction of antibacterial drugs, resistance to vector-borne diseases, and medical preparations of non-active ingredients. It can solve the problems that it is difficult for antibiotics to reach bactericidal concentrations and the clearance rate decreases.

Active Publication Date: 2020-11-24
SUN YAT SEN UNIV
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Based on this protective barrier, it is difficult for antibiotics to reach an effective bactericidal concentrat

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibacterial nanoparticles based on berberine derivatives and rhamnolipids
  • Antibacterial nanoparticles based on berberine derivatives and rhamnolipids
  • Antibacterial nanoparticles based on berberine derivatives and rhamnolipids

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0046] 1. Preparation and characterization of self-assembled nanoparticles

[0047] method

[0048] Preparation of berberine derivative / rhamnolipid self-assembled nanoparticles (BD / RHL NPs): Decylberberine derivative (C10-BD), dodecylberberine derivative (C10-BD) and dodecylberberine derivative ( C12-BD), cetyl berberine derivatives (C16-BD) and octadecyl berberine derivatives (C18-BD), were dissolved by adding DMSO sonication to make the concentration 5 mg / mL. Prepare a rhamnolipid (RHL) aqueous solution with a concentration of 2 mg / mL. Four kinds of berberine derivative (BD) solutions were added dropwise to the RHL solution under stirring, and the BD / RHL NPs were formed after the BD solution was dropped and continued to stir for 2 min. BD / RHL NPs were dialyzed in a 3500kD dialysis bag for 6h to remove organic solvents. Observe the appearance of the solution, and measure its particle size and potential.

[0049] The mass ratio screening of BD and RHL: Precisely absorb a c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention provides an antibacterial nanoparticle. The antibacterial nanoparticle is formed by self-assembling a berberine derivative and rhamnolipid. The invention provides application of the antibacterial nanoparticles in preparation of antibacterial preparations, and the bacteria are biofilm-producing bacteria including microaerophilic bacteria (such as H. Pylori), aerobic bacteria (such asP. Aeruginosa) and facultative anaerobic bacteria (such as E. Coli and S. Aureus), Anaerobic bacteria (e.g., S. Mutans), which encompass gram-negative bacteria and gram-positive bacteria. In one embodiment said biofilm-producing bacterium is H. Pylori.

Description

technical field [0001] The present invention relates to a nano drug delivery system, in particular to an antibacterial nano particle used to remove biofilms, especially a nano preparation used to kill or remove bacteria colonized in or under the mucus layer of epithelial cells. Background technique [0002] Helicobacter pylori (H. pylori) is a multi-flagellated, helical rod-shaped microaerophilic Gram-negative bacteria that can cause gastritis, gastric ulcer, gastric cancer and other malignant diseases. Early use of triple therapy with amoxicillin, clarithromycin, and proton pump inhibitors was used to treat H. pylori, and in the past few years, H. pylori resistance to antibiotics, including clarithromycin and metronidazole, has increased. increased. In order to improve the clearance rate of H.pylori, quadruple therapy derived from triple therapy has become the first-line treatment for H.pylori infection. Quadruple therapy adds bismuth on the basis of triple therapy to pro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/51A61K47/26A61K31/4375A61P31/04
CPCA61K9/5123A61K31/4375A61P31/04Y02A50/30
Inventor 胡海燕申元娜邹祎晴李彭宇陈小楠饶义琴
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products